{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:40:34Z","timestamp":1761946834539,"version":"3.37.3"},"reference-count":29,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,26]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>The majority of older adults or unfit acute leukemia patients are not offered intensive therapy, resulting in dismal long-term survival. A novel cytarabine prodrug BST-236 enables delivery of high-dose cytarabine and appears to be safe and efficacious in these patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000468","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T12:28:25Z","timestamp":1574771305000},"page":"3740-3749","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1\/2a study"],"prefix":"10.1182","volume":"3","author":[{"given":"Tsila","family":"Zuckerman","sequence":"first","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2013Israel Institute of Technology, Haifa, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Ram","sequence":"additional","affiliation":[{"name":"Hematology Division, Sourasky Medical Center, Tel-Aviv, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiza","family":"Akria","sequence":"additional","affiliation":[{"name":"Department of Hematology, Galil Medical Center, Nahariya, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7223-328X","authenticated-orcid":false,"given":"Maya","family":"Koren-Michowitz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Assaf Harofeh Medical Center, Zerifin, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2013Israel Institute of Technology, Haifa, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Henig","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Lavi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2013Israel Institute of Technology, Haifa, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5521-1337","authenticated-orcid":false,"given":"Yishai","family":"Ofran","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2013Israel Institute of Technology, Haifa, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Netanel A.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2013Israel Institute of Technology, Haifa, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Nudelman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigal","family":"Tavor","sequence":"additional","affiliation":[{"name":"Department of Hematology, Assuta Medical Center, Tel Aviv, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shay","family":"Yeganeh","sequence":"additional","affiliation":[{"name":"Department of Hematology, Poria Medical Center, Tiberias, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stela","family":"Gengrinovitch","sequence":"additional","affiliation":[{"name":"BioSight Ltd, Airport City, Lod, Israel; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liat","family":"Flaishon","sequence":"additional","affiliation":[{"name":"BioSight Ltd, Airport City, Lod, Israel; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoshi","family":"Tessler","sequence":"additional","affiliation":[{"name":"BioSight Ltd, Airport City, Lod, Israel; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Ben Yakar","sequence":"additional","affiliation":[{"name":"BioSight Ltd, Airport City, Lod, Israel; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2013Israel Institute of Technology, Haifa, Israel;"},{"name":"Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"issue":"1","key":"2019112611385068100_B1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019112611385068100_B2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2019112611385068100_B3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.1991.9.4.679","article-title":"Cytarabine and neurologic toxicity","volume":"9","author":"Baker","year":"1991","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019112611385068100_B4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"issue":"3","key":"2019112611385068100_B5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2125.1979.tb01005.x","article-title":"Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia","volume":"8","author":"Harris","year":"1979","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2019112611385068100_B6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/bloodadvances.2017014126","article-title":"CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine","volume":"2","author":"Fanciullino","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"2019112611385068100_B7","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.2217\/pgs.09.118","article-title":"Genetic factors influencing cytarabine therapy","volume":"10","author":"Lamba","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"suppl 1","key":"2019112611385068100_B8","article-title":"BST-236, a novel cytarabine pro-drug, enables safe and effective administration of high dose cytarabine to older or unfit patients with acute leukemia. Results of a phase I\/II study [abstract]","volume":"130","author":"Zuckerman","year":"2017","journal-title":"Blood"},{"doi-asserted-by":"crossref","unstructured":"Tessler\n              S\n            , MishalianI, Peri-NaorR, et al BST-236, a novel cytarabine prodrug, is safer and as effective as cytarabine in in vivo leukemia models [abstract]. Blood. 2018;132(suppl 1). Abstract 1451.","key":"2019112611385068100_B9","DOI":"10.1182\/blood-2018-99-112092"},{"issue":"12","key":"2019112611385068100_B10","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"issue":"18","key":"2019112611385068100_B11","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019112611385068100_B12","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"issue":"21","key":"2019112611385068100_B13","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019112611385068100_B14","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019112611385068100_B15","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/blood-2013-04-496596","article-title":"Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival","volume":"122","author":"Burnett","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2019112611385068100_B16","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/cncr.28113","article-title":"Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"issue":"19","key":"2019112611385068100_B17","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1182\/blood-2014-10-608117","article-title":"Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia","volume":"125","author":"Dennis","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019112611385068100_B18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"Cashen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019112611385068100_B19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","article-title":"A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy","volume":"97","author":"Lubbert","year":"2012","journal-title":"Haematologica"},{"issue":"6","key":"2019112611385068100_B20","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"2019112611385068100_B21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019112611385068100_B22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1200\/JCO.1983.1.12.763","article-title":"Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia","volume":"1","author":"Capizzi","year":"1983","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019112611385068100_B23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00686248","article-title":"Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside","volume":"29","author":"DeAngelis","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3-4","key":"2019112611385068100_B24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/10428199709059686","article-title":"Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal","volume":"27","author":"Burk","year":"1997","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019112611385068100_B25","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1365-2141.2012.09076.x","article-title":"Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure","volume":"157","author":"Pr\u00e9bet","year":"2012","journal-title":"Br J Haematol"},{"issue":"26","key":"2019112611385068100_B26","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019112611385068100_B27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2019112611385068100_B28","article-title":"Phase 1\/2 study of venetoclax with low-dose cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1-year outcomes [abstract]","volume":"130","author":"Wei","year":"2017","journal-title":"Blood"},{"doi-asserted-by":"crossref","unstructured":"Wei\n              AH\n            , TiongIS, RobertsAW, et al Chemotherapy and venetoclax in elderly AML trial (CAVEAT): a phase 1B dose escalation study examining modified intensive chemotherapy in fit elderly patients. In: Abstract Book of the 23rd Congress of the European Hematology Association; 14-17 June 2018; Stockholm, Sweden. Abstract S1564.","key":"2019112611385068100_B29","DOI":"10.1097\/HS9.0000000000000060"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/22\/3740\/1543390\/advancesadv2019000468.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/22\/3740\/1543390\/advancesadv2019000468.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T12:28:34Z","timestamp":1574771314000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/22\/3740\/428880\/BST236-a-novel-cytarabine-prodrug-for-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":29,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,11,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000468","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2019,11,26]]}}}